General InformationIsomorphic Labs is an AI-driven drug discovery company based in San Francisco with approximately 50-150 employees, founded in 2021 as a spinout from DeepMind.
Funding & FinancialsThe company has raised over $200 million including a Series B round led by major investors, with backing from Lowercarbon Capital and other prominent deep-tech VCs.
Leadership & TeamFounded by Demis Hassabis (CEO, co-founder of DeepMind) and other senior researchers from DeepMind and academia, bringing world-class AI expertise to drug development.
Recent ActivityIsomorphic Labs announced partnerships with major pharmaceutical companies and published research demonstrating AI-predicted protein structures advancing toward clinical validation in 2023-2024.